Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline in Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
NCT04630145Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of bedaquiline in Mycobacterium avium complex lung disease, sponsored by Janssen Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
bedaquiline
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT04630145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630145.